Piracetam
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Piracetam: From Myoclonus to Osteoarthritis
One-Sentence Summary
Piracetam is a cyclic GABA derivative (nootropic) that is approved in the UK for myoclonus (in combination with other anti-myoclonic therapies) and used in several European, Asian, and South American countries for cognitive/circulatory indications, but it is not marketed in Taiwan and not FDA-approved. The TxGNN model predicts it may be effective for Osteoarthritis, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure model-embedding signal with no external validation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not marketed in Taiwan (0 licenses); internationally approved for myoclonus (UK), per DrugBank pharmacology record |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 98.45% |
| Evidence Level | L5 (model prediction only) |
| Taiwan Market Status | Not marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Piracetam’s original_moa field is a formal data gap, but the DrugBank pharmacology record captures its known target profile: it binds the AMPA-type ionotropic glutamate receptor subunits GluA1–GluA4 (genes GRIA1–GRIA4), consistent with its established nootropic/anti-myoclonic effects. Its clinically documented actions center on neuronal membrane fluidity, red blood cell deformability, and microcirculation — it is used for myoclonus and, in some jurisdictions, for cognitive and vascular indications.
Osteoarthritis, by contrast, is driven by cartilage degradation, chondrocyte senescence, and local joint inflammation — pathways with no established connection to glutamate-receptor modulation or hemorheology. The model’s own rationale is explicit on this point: “no known mechanistic overlap between piracetam’s known pharmacology and osteoarthritis cartilage degeneration or joint inflammation pathways.”
In short, this is a case where the TxGNN embedding score is high (98.45%, rank 21,123) but is not corroborated by any independent mechanistic, preclinical, or clinical signal. The prediction should be read as a hypothesis-generating signal only, not as evidence of therapeutic plausibility.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Piracetam is not marketed in Taiwan — total_licenses = 0, no product registrations on file. No dosage forms or approved indications are available for the local market.
Safety Considerations
TFDA-specific warnings and contraindications are not currently available (blocking data gap — see Conclusion below). No package-insert-level DDI list was returned; the pharmacology data on file describes piracetam’s AMPA-receptor target-binding profile (GluA1–GluA4) rather than drug-drug interactions, so it is reported under mechanism above instead of as a safety warning.
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction sits at decision stage S0 with Evidence Level L5 — a TxGNN score alone, with zero supporting clinical trials or literature, and an explicit mechanistic mismatch between piracetam’s known glutamatergic/hemorheological activity and osteoarthritis pathophysiology. There is no basis to advance this candidate at this time.
To proceed, the following is needed:
- TFDA/manufacturer package insert (warnings, contraindications) — currently a blocking data gap (DG001) that prevents entry into the S1 safety pre-screen
- Confirmed mechanism-of-action documentation beyond the raw pharmacology target list (DG002)
- Preclinical or observational evidence directly linking piracetam to cartilage/joint inflammation pathways before any clinical exploration is considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.